Repeated Ketamine Infusions Linked to Rapid Relief of PTSD Deborah Brauser Medscape. com, January 18, 2021 Medscape Medical News © 2021 www.medscape.com/viewarticle/944282_print Repeated intravenous infusions of ketamine provide rapid relief for patients with posttraumatic stress disorder (PTSD), new research suggests. In what investigators are calling the first randomized controlled trial of repeated ketamine administration for chronic PTSD, 30 patients received six infusions of ketamine or midazolam (used as a psychoactive placebo) over 2 consecutive weeks. Between baseline and week 2, those receiving ketamine showed significantly greater improvement than those receiving midazolam. Total scores on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) for the first group were almost 12 points [...]
Lire la suiteChanges in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca Nicole Leite Galvão-Coelho, Ana Cecília de Menezes Galvão, Raíssa Nóbrega de Almeida, Fernanda Palhano-Fontes, Isaac Campos Braga, Bruno Lobão Soares, João Paulo Maia-de-Oliveira, Daniel Perkins, Jerome Sarris and Draulio Barros de Araujo Journal of Psychopharmacology, 2020, 1-9. DOI : 10.1177/0269881120936486 Abstract Background : Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scientific settings. We conducted a double-blind placebo-controlled trial of ayahuasca with treatment-resistant depression patients (n = 28) and healthy controls (n = 45). Aims : We are evaluating the blood inflammatory biomarkers: C-reactive protein and [...]
Lire la suiteNeuroprotection Following Concussion : The Potential Role for Cannabidiol Jyotpal Singh, John Patrick Neary Canadian Journal of Neurological Sciences, 2020, 1–12 doi : 10.1017/cjn.2020.23 ABSTRACT : Cannabidiol (CBD) has been generating increasing interest in medicine due to its therapeutic properties and an apparent lack of negative side effects. Research has suggested that high dosages of CBD can be taken acutely and chronically with little to no risk. This review focuses on the neuroprotective effects of a CBD, with an emphasis on its implications for recovering from a mild traumatic brain injury (TBI) or concussion. CBD has been shown to influence the endocannabinoid system, both by [...]
Lire la suiteReviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/ Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]
Lire la suiteDrogues : la pénalisation de l'usage inefficace pour deux-tiers des Français Par Le Figaro avec AFP 21/01/2021 - Publié il y a 5 heures Une consultation citoyenne en ligne sur le cannabis dit «récréatif» a été lancée le 13 janvier. LOIC VENANCE / AFP Les deux tiers des Français jugent la pénalisation de l'usage des drogues inefficace pour lutter pour la consommation (66%) et les trafics (69%), selon un sondage CSA publié jeudi 21 janvier par plusieurs associations. À lire aussi :Un livreur de drogue à domicile tombe en panne et se fait interpeller Les trois-quarts (73%) d'entre eux estiment par ailleurs insuffisantes les campagnes de prévention [...]
Lire la suiteU.N. drug agency loosens global controls on cannabis, following WHO advice By Reuters Staff, 2 décembre 2020 https://www.reuters.com/article/idUSKBN28C336 VIENNA (Reuters) - The U.N. drug agency’s member states on Wednesday narrowly voted to remove cannabis from the most tightly controlled category of narcotic drugs, following the World Health Organization’s recommendation to make research into its medical use easier. The annual Commission on Narcotic Drugs, the U.N. Office on Drugs and Crime’s governing body, voted 27-25 with one abstention to remove cannabis and cannabis resin from Schedule IV of the 1961 Single Convention on Narcotic Drugs, a global text governing drug controls, a U.N. statement said. The [...]
Lire la suiteAdd-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex. A Placebo-Controlled Randomized Clinical Trial Elizabeth A. Thiele, MD, PhD; E. Martina Bebin, MD, MPA; Hari Bhathal, MD; Floor E. Jansen, MD; Katarzyna Kotulska, MD, PhD; John A. Lawson, BMed, PhD; Finbar J. O'Callaghan, MBChB, PhD; MichaelWong,MD, PhD; Farhad Sahebkar, MD; Daniel Checketts, MSc; Volker Knappertz, MD; for the GWPCARE6 Study Group JAMA Neurology, 2020, December 21 online, E1-E7. doi : 10.1001/jamaneurol.2020.4607 IMPORTANCE : Efficacy of cannabidiol has been demonstrated in seizures associated with Lennox-Gastaut and Dravet syndromes but appears not yet to have been established in conditions with primarily focal seizures, such as [...]
Lire la suiteCannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]
Lire la suiteNouvelle classification du cannabis : le service minimum de la Commission des stupéfiants de l’ONU par L630 | Déc 2, 2020 | Communiqué https://l630.org/nouvelle-classification-du-cannabis-le-service-minimum-de-la-commission-des-stupefiants-de-lonu/ Ce 12 décembre, la Commission des stupéfiants des Nations-Unies a décidé de modifier la classification du cannabis au sein des conventions internationales. Le cannabis n’est plus classé comme un stupéfiant du tableau IV, c’est-à-dire ayant un potentiel d’abus fort et des effets nocifs importants, sans valeur thérapeutique notable. L630 réagit. COMMUNIQUE DE PRESSE. L630 se félicite de la décision de la Commission des Stupéfiants des Nations-Unies de retirer le cannabis du tableau des stupéfiants sans intérêt médical. Cette décision [...]
Lire la suiteLe CBD enfin légal ? La décision de la Cour européenne sur l’affaire Kanavape est une claque pour la France par L630 | Nov 19, 2020 | Actualité juridique, Communiqué https://l630.org/le-cbd-enfin-legal-la-decision-de-la-cour-europeenne-sur-laffaire-kanavape-est-une-claque-pour-la-france/ Paris, le 19 novembre 2020. Nous apprenons à l’instant la publication de la décision de la Cour de Justice de l’Union Européenne à propos de l’affaire dite Kanavape. C’est une victoire retentissante pour les demandeurs (Antonin Cohen et Sébastien Béguerie). L630 salue cette décision qui confirme sa position historique. La Cour de Justice de l’Union Européenne conclut à la réaffirmation du principe de libre circulation des marchandises et des biens, autorisant donc [...]
Lire la suite